^
Association details:
| Biomarker: | BIRC2 overexpression + BIRC3 overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | AZD5582 (IAP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BIRC2-BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia
Published date:
01/07/2022
Excerpt:
We then found the drug AZD5582, a known small molecule inhibitor of BIRC2-3, to selectively kill FA tumor cells that overexpressed BIRC2-3. This occurred at drug concentrations that did not affect the viability of untransformed FA cells....Therefore, chemotherapeutic inhibition of overexpressed BIRC2-3 may provide the basis for an approach to develop a clinically realistic treatment of FA-HNSCCs...
DOI:
10.1038/s41598-021-04042-9
